Previous 10 | Next 10 |
C4 Therapeutics (CCCC) announces that it has decided to advance CFT8919, a novel degrader of epidermal growth factor receptor ((EGFR)) in non-small cell lung cancer ((NSCLC)), into investigational new drug ((IND))-enabling studies.The company also said that it anticipates filing an IND for th...
– IND Submission for CFT8919 Anticipated mid-2022; Phase 1/2 Trial Initiation Expected by YE 2022 – – CFT8919 is Potent and Mutant-Selective BiDAC T M Degrader of EGFR L858R for the Treatment of Non-Small Cell Lung Cancer – ...
C4 Therapeutics (CCCC) has appointed Lauren White as its new chief financial officer.White, who will begin on June 21, takes over from interim CFO William McKee.White was previously in the global finance division at Novartis.C4 shares closed up 3.7% to $35.60. For further details ...
C4 Therapeutics (CCCC) announces the appointment of Lauren White as the company's chief financial officer, effective June 21, 2021. White’s appointment will initiate William McKee’s planned transition from interim chief financial officer, a role he has held since ...
WATERTOWN, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the appointment of Lauren Whit...
C4 Therapeutics (CCCC): Q1 GAAP EPS of -$0.49 beats by $0.14.Revenue of $7.43M (+8.9% Y/Y) beats by $4.7M.Press Release For further details see: C4 Therapeutics EPS beats by $0.14, beats on revenue
– Preclinical Data for CFT7455, a novel IKZF1/3 Degrader, in Non-Hodgkin's Lymphoma Xenograft Models Accepted for Presentation at the International Conference on Malignant Lymphoma (ICML) in June – – CFT7455 Phase 1/2 Clinical Trial in Multiple Myeloma and...
WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will particip...
– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models – – CFT7455 Promotes Sustained Degradation of IKZF1/3 and Durable Anti-t...
C4 Therapeutics (CCCC): FY GAAP EPS of -$5.83 beats by $5.25.Revenue of $31.19M (+45.9% Y/Y) misses by $1.73M.Press Release For further details see: C4 Therapeutics EPS beats by $5.25, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...